It is reported that a low FASL/FAS ratio in tumors is a negative prognostic marker, and the administration of tumor-targeted antibodies fused to FASL could be a future therapeutic alternative in such patients [38,39,40]. The gene discussed is FASLG; the disease is neoplasm.